Unlike GLP-1 receptor agonists, which enhance insulin secretion and sensitivity, SGLT2 inhibitors complement diabetes management by reducing glucose reabsorption in the kidneys, promoting glycosuria, and subsequently lowering blood glucose levels. This evidence concerns the gene SLC5A2 and diabetes mellitus.